Datapoint: Roche Scores Expanded SMA Nod for Evrysdi
June
2
The FDA this week approved Roche’s at-home spinal muscular atrophy (SMA) therapy Evrysdi in children under two months old. The treatment was first approved for SMA in adults and older children in August 2020. It currently holds covered or better status for 81% of all insured lives under the pharmacy benefit.
SOURCE: MMIT Analytics, as of 6/1/22
© 2025 MMIT
